This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Inglewood, California-based biotechnology company ImaginAb is the seller, unloading a pipeline of drug candidates, technology platform and research facility.
Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.
Telix Pharmaceuticals has entered an agreement to add Subtle Medical’s AI software for enhancing prostate-specific membrane antigen (PSMA) PET prostate cancer scans to its product portfolio. SubtlePET is a U.S.
Telix Pharmaceuticals Ltd. announced the news on July 31, with the decision applying to its TLX250-CDx investigational agent for clear cell renal cell carcinoma (brand name Zircaix).
Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225). Actinium will continue developing its lead radiopharmaceutical product Actimab-A, as well as additional early and late-stage development candidates for both U.S. and international clinical trials.
Shuttle Pharmaceuticals Holdings has closed a previously announced underwritten public common stock offering, with aggregate gross proceeds of approximately $5.8 The Gaithersburg, MD-based specialty pharmaceutical company offered 19.1 million shares of its common stock at a public offering price of 30 per share.
Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).
The facility will provide much needed developmental and manufacturing support for pharmaceutical companies that produce and distribute medical isotopes.
Backers include societies representing radiologists and nuclear medicine professionals, device manufacturers, patient advocacy groups, and pharmaceutical companies.
Radiotherapy developer Actinium Pharmaceuticals is launching ATNM-400, a novel, non-prostate-specific membrane antigen (PSMA) targeting radiotherapy for prostate cancer that uses the actinium-225 (Ac-225) radioisotope.
Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.
Telix Pharmaceuticals has entered into an asset purchase agreement with ImaginAb initially worth $45 million. Under terms of the deal, Telix will acquire a pipeline of therapeutic candidates such as DLL3 and integrin v6, a biologics technology platform, and a protein engineering and discovery research facility in California, it said.
milla1cf Tue, 01/23/2024 - 13:50 January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich , Member of the Board of Management, Bayer AG, and President Pharmaceuticals.
Fusion Pharmaceuticals announced a patent dispute settlement and new licensing agreement with Heidelberg University and Euratom for exclusive, worldwide rights to their existing patent for FPI-2265, an actinium-225-based targeted radiotherapy for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers.
Telix Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for a new prostate-specific membrane antigen (PSMA)-PET cold kit for prostate cancer imaging.
NorthStar Medical Radioisotopes is routinely manufacturing copper-67(Cu-67. Read more on AuntMinnie.com Related Reading: NorthStar appoints new president/CEO NorthStar installs accelerator at its new Wisc.
For one pharmaceutical company, a plan to independently source barium and iodine from North America may offer protection from global supply chain disruptions.
The group analyzed flortaucipir (Tauvid, Avid Pharmaceuticals) PET scans acquired over a 3.5-year Moreover, currently, approximately a quarter of postmenopausal women who are 70 years and older have a history of HT use and have now entered a critical age of risk for Alzheimers disease, the authors added.
We designed RXM-4768 with the unique requirements for SCINTIX therapy in mind, and our preclinical data demonstrated its potential as an effective biology guide for potentially most solid tumor cancer types,” said Dr. Ulrich Reineke , founder & managing director of 3B Pharmaceuticals. “We
Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx (Zr-89 DFO-girentuximab) for clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.
NETTER-P was conducted as part of a pediatric Written Request under the Best Pharmaceuticals for Children Act, the FDA stated. The application was granted priority review and orphan drug designation. A postmarketing requirement was issued to assess the long-term safety of Lu-177 DOTATATE in adolescents.
It’s also primed to revolutionize the pharmaceutical industry. This is where MRI Network recruiters focused on the pharmaceutical industry come into play. Generative AI systems can also track company leadership and researchers responsible for key decisions from program initiation to completion.
Australia-based Telix Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) to list its ordinary shares and trade on the Nasdaq under the ticker symbol “TLX.” Telix is not proposing to raise capital or issue any new shares, it said.
Produced by the ACR Committee on Drugs and Contrast Media, the new manual features four updates: An update and addition of Ferumoxytol as a new MRI contrast medium for Chapter 12 – Contrast Media in Children An update for Chapter 13 - Gastrointestinal (GI) Contrast Media in Adults: Indications and Guidelines An evidence-based update with recommendations (..)
With her large experience in the pharmaceutical industry, Helen Blanco currently serves as Chief Operating Officer at Node Pharma , a preclinical radiopharmaceutical company based in Norway. Here is another excerpt from our conversation.
Emery has more than 30 years of experience in financial executive leadership in the pharmaceutical and medical device industries. Prior to that, he led financial executive teams at Plasma Surgical and Abbott Pharmaceuticals. He was previously CFO and chief operating officer (COO) at Tyber Medical.
He will oversee Lantheus’ research and development organization, including research and pharmaceutical development, regulatory affairs, clinical development, medical affairs, and isotope strategy. He has spent more than two decades working for pharmaceutical companies such as Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.
ICH Q10 is a global model for managing pharmaceutical quality, ensuring compliance, continuous improvement, and risk manage The post The International Council for Harmonization (ICH) Q10: A Model for a Robust Pharmaceutical Quality Management System appeared first on Open MedScience.
Carestream Health has secured a distribution contract for its radiology, cardiology, urology, endoscopy, and pharmaceutical offerings with BSF Medical - SARL of Bir El Djir, Algeria. BSF Medical - SARL is one of Algeria's largest medical equipment distributors in both public and private sectors, Carestream said.
hospitals and pharmaceutical companies and that QP-Prostate was initially cleared in 2021 for automated segmentation of prostate regions. Quibim, based in Valencia, Spain, noted that it recently closed on $50 million in financing to support strategic collaborations with U.S.
Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., subject to its regulatory approval.
In previous smaller studies , zirconium-89 (Zr-89) girentuximab (Zircaix, Telix Pharmaceuticals) PET/CT imaging differentiated ccRC tumors from other kidney tumor types based on its ability to bind to carbonic anhydrase 9 (CAIX), an antigen highly expressed by ccRCC cancer cells.
GE HealthCare (GEHC) reported a 1% growth in existing operation revenues and an increase in profitability in its second quarter of 2024, citing solid performance in its Pharmaceutical Diagnostics segment. For the period (end-September 30), GEHC had total revenues of $4.86 billion, flat compared with $4.82 billion in the same period last year.
Radiopharmaceutical developer Actinium Pharmaceuticals is highlighting six researc. Read more on AuntMinnie.com Related Reading: Actinium, Astellas to create actinium-225 radiotherapies Zevacor signs on as manufacturing partner for Actinium
The company’s Pharmaceutical Diagnostics segment generated $639 million in second-quarter revenues, a 14% increase on an organic basis over last year, GE HealthCare reported. Pharmaceutical Diagnostics segment EBIT was $200 million, up 31% over last year. Segment EBIT was $178 million, down 7% from the second quarter of 2023.
Originally started as an executive recruiting firm focused on the pharmaceutical industry, it quickly evolved into an IT recruiting firm with a strong focus on Cyber Security. He also worked in the telecom/Internet industry for McLeod USA, as well as a Pharmaceutical rep for Sepracor in Minneapolis, MN.
Radiotherapy developer Actinium Pharmaceuticals will present three abstract. Read more on AuntMinnie.com Related Reading: Actinium highlights six abstracts at SNMMI 2023 Actinium, Astellas to create actinium-225 radiotherapies SNMMI 2020: PET tracer could image, treat glioblastoma Zevacor signs on as manufacturing partner for Actinium
from Cardinal Health FDA clears Cardinal's Lymphoseek for pediatric use Cardinal Health joins SNMMI's Value Initiative Cardinal Health taps new head of pharmaceutical unit Read more on AuntMinnie.com Related Reading: Navidea secures $7.5M
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content